Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
36
GSK Quote, Financials, Valuation and Earnings
Last price:
$48.99
Seasonality move
:
6.89%
Day range:
$48.69 - $49.04
52-week range:
$31.72 - $49.44
Dividend yield:
3.42%
P/E ratio:
13.96x
P/S ratio:
2.40x
P/B ratio:
4.53x
Volume:
1.1M
Avg. volume:
4M
1-year change:
43.87%
Market cap:
$98.4B
Revenue:
$40.1B
EPS (TTM):
$3.51
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GSK
GSK Plc
|
$11B | $1.26 | 8.14% | 137.07% | $49.35 |
|
AUTL
Autolus Therapeutics Plc
|
$21.3M | -$0.23 | 84624.25% | -288.08% | $9.52 |
|
AZN
AstraZeneca PLC
|
$14.8B | $1.13 | 4.56% | 128.14% | $98.96 |
|
BCYC
Bicycle Therapeutics Plc
|
$8.2M | -$1.07 | 92.62% | -25.75% | $21.50 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GSK
GSK Plc
|
$48.96 | $49.35 | $98.4B | 13.96x | $0.42 | 3.42% | 2.40x |
|
AUTL
Autolus Therapeutics Plc
|
$1.68 | $9.52 | $447.1M | -- | $0.00 | 0% | 8.72x |
|
AZN
AstraZeneca PLC
|
$92.48 | $98.96 | $286.7B | 30.71x | $0.52 | 1.69% | 4.97x |
|
BCYC
Bicycle Therapeutics Plc
|
$6.99 | $21.50 | $484.9M | -- | $0.00 | 0% | 17.09x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.87 | $17.94 | $2.4M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$3.31 | $104.00 | $13.8M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GSK
GSK Plc
|
52.36% | -0.071 | 27.67% | 0.53x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
AZN
AstraZeneca PLC
|
41.56% | 0.163 | 13.71% | 0.66x |
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 2.129 | 1.21% | 9.36x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GSK
GSK Plc
|
$8.5B | $3.5B | 19.21% | 42.84% | 30.08% | $1.8B |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
AZN
AstraZeneca PLC
|
$11.2B | $3.6B | 12.62% | 22.01% | 23.52% | $3.5B |
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
GSK Plc vs. Competitors
-
Which has Higher Returns GSK or AUTL?
Autolus Therapeutics Plc has a net margin of 25.09% compared to GSK Plc's net margin of -373.3%. GSK Plc's return on equity of 42.84% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK Plc73.8% $1.32 $45.1B AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About GSK or AUTL?
GSK Plc has a consensus price target of $49.35, signalling upside risk potential of 0.79%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 480.62%. Given that Autolus Therapeutics Plc has higher upside potential than GSK Plc, analysts believe Autolus Therapeutics Plc is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK Plc1 5 1 AUTLAutolus Therapeutics Plc9 0 0 -
Is GSK or AUTL More Risky?
GSK Plc has a beta of 0.470, which suggesting that the stock is 52.951% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock GSK or AUTL?
GSK Plc has a quarterly dividend of $0.42 per share corresponding to a yield of 3.42%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK Plc pays 94.89% of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GSK or AUTL?
GSK Plc quarterly revenues are $11.5B, which are larger than Autolus Therapeutics Plc quarterly revenues of $21.1M. GSK Plc's net income of $2.9B is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, GSK Plc's price-to-earnings ratio is 13.96x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.40x versus 8.72x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK Plc2.40x 13.96x $11.5B $2.9B AUTLAutolus Therapeutics Plc8.72x -- $21.1M -$78.6M
-
Which has Higher Returns GSK or AZN?
AstraZeneca PLC has a net margin of 25.09% compared to GSK Plc's net margin of 16.69%. GSK Plc's return on equity of 42.84% beat AstraZeneca PLC's return on equity of 22.01%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK Plc73.8% $1.32 $45.1B AZNAstraZeneca PLC73.89% $0.81 $78.6B -
What do Analysts Say About GSK or AZN?
GSK Plc has a consensus price target of $49.35, signalling upside risk potential of 0.79%. On the other hand AstraZeneca PLC has an analysts' consensus of $98.96 which suggests that it could grow by 7.4%. Given that AstraZeneca PLC has higher upside potential than GSK Plc, analysts believe AstraZeneca PLC is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK Plc1 5 1 AZNAstraZeneca PLC8 1 0 -
Is GSK or AZN More Risky?
GSK Plc has a beta of 0.470, which suggesting that the stock is 52.951% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.315, suggesting its less volatile than the S&P 500 by 68.471%.
-
Which is a Better Dividend Stock GSK or AZN?
GSK Plc has a quarterly dividend of $0.42 per share corresponding to a yield of 3.42%. AstraZeneca PLC offers a yield of 1.69% to investors and pays a quarterly dividend of $0.52 per share. GSK Plc pays 94.89% of its earnings as a dividend. AstraZeneca PLC pays out 66.98% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GSK or AZN?
GSK Plc quarterly revenues are $11.5B, which are smaller than AstraZeneca PLC quarterly revenues of $15.1B. GSK Plc's net income of $2.9B is higher than AstraZeneca PLC's net income of $2.5B. Notably, GSK Plc's price-to-earnings ratio is 13.96x while AstraZeneca PLC's PE ratio is 30.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.40x versus 4.97x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK Plc2.40x 13.96x $11.5B $2.9B AZNAstraZeneca PLC4.97x 30.71x $15.1B $2.5B
-
Which has Higher Returns GSK or BCYC?
Bicycle Therapeutics Plc has a net margin of 25.09% compared to GSK Plc's net margin of -503.67%. GSK Plc's return on equity of 42.84% beat Bicycle Therapeutics Plc's return on equity of -34.37%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK Plc73.8% $1.32 $45.1B BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M -
What do Analysts Say About GSK or BCYC?
GSK Plc has a consensus price target of $49.35, signalling upside risk potential of 0.79%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $21.50 which suggests that it could grow by 209.8%. Given that Bicycle Therapeutics Plc has higher upside potential than GSK Plc, analysts believe Bicycle Therapeutics Plc is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK Plc1 5 1 BCYCBicycle Therapeutics Plc6 4 0 -
Is GSK or BCYC More Risky?
GSK Plc has a beta of 0.470, which suggesting that the stock is 52.951% less volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.475, suggesting its more volatile than the S&P 500 by 47.505%.
-
Which is a Better Dividend Stock GSK or BCYC?
GSK Plc has a quarterly dividend of $0.42 per share corresponding to a yield of 3.42%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK Plc pays 94.89% of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GSK or BCYC?
GSK Plc quarterly revenues are $11.5B, which are larger than Bicycle Therapeutics Plc quarterly revenues of $11.7M. GSK Plc's net income of $2.9B is higher than Bicycle Therapeutics Plc's net income of -$58.7M. Notably, GSK Plc's price-to-earnings ratio is 13.96x while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.40x versus 17.09x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK Plc2.40x 13.96x $11.5B $2.9B BCYCBicycle Therapeutics Plc17.09x -- $11.7M -$58.7M
-
Which has Higher Returns GSK or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of 25.09% compared to GSK Plc's net margin of --. GSK Plc's return on equity of 42.84% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK Plc73.8% $1.32 $45.1B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About GSK or BDRX?
GSK Plc has a consensus price target of $49.35, signalling upside risk potential of 0.79%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 5406.23%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than GSK Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK Plc1 5 1 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is GSK or BDRX More Risky?
GSK Plc has a beta of 0.470, which suggesting that the stock is 52.951% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock GSK or BDRX?
GSK Plc has a quarterly dividend of $0.42 per share corresponding to a yield of 3.42%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK Plc pays 94.89% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GSK or BDRX?
GSK Plc quarterly revenues are $11.5B, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. GSK Plc's net income of $2.9B is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, GSK Plc's price-to-earnings ratio is 13.96x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.40x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK Plc2.40x 13.96x $11.5B $2.9B BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns GSK or NCNA?
NuCana Plc has a net margin of 25.09% compared to GSK Plc's net margin of --. GSK Plc's return on equity of 42.84% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital GSKGSK Plc73.8% $1.32 $45.1B NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About GSK or NCNA?
GSK Plc has a consensus price target of $49.35, signalling upside risk potential of 0.79%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 628298.79%. Given that NuCana Plc has higher upside potential than GSK Plc, analysts believe NuCana Plc is more attractive than GSK Plc.
Company Buy Ratings Hold Ratings Sell Ratings GSKGSK Plc1 5 1 NCNANuCana Plc0 1 0 -
Is GSK or NCNA More Risky?
GSK Plc has a beta of 0.470, which suggesting that the stock is 52.951% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.
-
Which is a Better Dividend Stock GSK or NCNA?
GSK Plc has a quarterly dividend of $0.42 per share corresponding to a yield of 3.42%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GSK Plc pays 94.89% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. GSK Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios GSK or NCNA?
GSK Plc quarterly revenues are $11.5B, which are larger than NuCana Plc quarterly revenues of --. GSK Plc's net income of $2.9B is higher than NuCana Plc's net income of -$378.9K. Notably, GSK Plc's price-to-earnings ratio is 13.96x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GSK Plc is 2.40x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GSKGSK Plc2.40x 13.96x $11.5B $2.9B NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
